intrommune_icon_500x500.png
Intrommune Therapeutics Strengthens Board of Directors with Appointments of Dr. Jonathan Rich and Hem Pandya
March 12, 2024 11:01 ET | Intrommune Therapeutics
Intrommune Therapeutics today announced the appointment of Dr. Jonathan Rich to its board of directors and Hem Pandya as Executive Chairman of the board.
intrommune_icon_500x500.png
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
February 22, 2024 09:34 ET | Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
Sunshine Care
Sunshine Care Announces Final Advisory Board and General Counsel, Sets Franchising Milestones
February 17, 2022 00:36 ET | Sunshine Care Partners
ANNAPOLIS, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sunshine Care is proud to announce its Advisory Board membership and responsibilities for each member. Sunshine Care national franchises will be...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference
May 17, 2019 13:25 ET | Intrommune Therapeutics
New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy
March 08, 2019 10:01 ET | Intrommune Therapeutics
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
Intrommune Logo Only - 250k.jpg
Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment
November 08, 2018 16:44 ET | Intrommune Therapeutics
New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...